<DOC>
	<DOCNO>NCT00675948</DOCNO>
	<brief_summary>The purpose study assess safety tolerability long term therapy Sativex® GW-2000-02 .</brief_summary>
	<brief_title>Study Compare Safety Tolerability Sativex® Patients With Cancer Related Pain</brief_title>
	<detailed_description>Subjects previously participate GWCA0101 , two week ( two day baseline two week treatment period ) , multicentre , double blind , randomise , placebo control , parallel group study evaluate efficacy Sativex® ( contain delta-9-tetrahydrocannabinol [ THC ] cannabidiol [ CBD ] ) GW-2000-02 ( contain THC alone ) subject cancer-related pain screen , eligible begin dose open-label Sativex® . They allow self-titrate study medication symptom resolution maximum tolerated/allowable dose 130 mg THC 120 mg CBD opportunity request change Sativex® GW-2000-02 investigator consider response less optimal . Subjects review tolerability evidence clinical benefit 7-10 day Visit 1 every four week . Continuation within study conditional satisfactory report tolerability , efficacy dose regime .</detailed_description>
	<criteria>Willing eligible continue extension study GWCA0101 . Complied adequately study requirement , detailed GWCA0101 . In investigator 's opinion able undertake comply study requirement ( understood progress disease may accelerate affect ability ) . Willing able read , consider understand subject information consent form give write informed consent compliance Declaration Helsinki1 . Willing allow general practitioner , consultant appropriate , inform study participation . Willing name notify Home Office participation trial . Have participate GWCA0101 . Have comply adequately study requirement , detailed GWCA0101 . Experienced unacceptable adverse event , whilst participate GWCA0101 . Known suspect adverse reaction cannabinoids cause psychosis severe psychiatric illness . History type schizophrenia , psychotic illness , serious personality disorder , significant psychiatric illness depression associate chronic pain and/or response underlie condition . Currently take levodopa ( Sinemet® , Sinemet plus® , Levodopa® , Ldopa® , Madopar® , Benserazide® ) . Has serious cardiovascular disorder , include angina , uncontrolled hypertension , uncontrolled symptomatic cardiac arrhythmia . Has significant renal hepatic impairment , opinion investigator , unsuitable treatment Investigational Medicinal Product . History epilepsy . Female subject child bear potential male subject whose partner child bear potential , unless willing ensure partner use effective contraception study three month thereafter . If female , pregnant lactating , plan pregnancy course study three month thereafter . Have oral cavity cancer whose previous treatment include radiotherapy floor mouth . In opinion investigator , unsuitable participate study reason , mention inclusion exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Palliative Care</keyword>
	<keyword>Pain</keyword>
	<keyword>Cancer</keyword>
</DOC>